Pharmacophore-based designing of putative ROS-1 targeting agents for NSCLC

Area of Science:

• Medicinal Chemistry
• Oncology
• Computational Chemistry

Background:

• Non-small cell lung cancer (NSCLC) is a significant cause of cancer mortality.
• Proto-oncogene receptor tyrosine kinase (ROS-1) is a key biomarker in certain NSCLC cases.
• Targeting ROS-1 offers a therapeutic strategy for NSCLC treatment.

Purpose of the Study:

• To design and synthesize novel benzimidazol-2-amine derivatives.
• To evaluate the anti-proliferative activity of these compounds against NSCLC cells.
• To explore structure-based drug design for ROS-1 inhibitors.

Main Methods:

• Pharmacophore modeling and in silico screening of small molecule heterocycles against ROS-1.
• Molecular docking and dynamics simulations to assess binding affinity and stability.
• Chemical synthesis of benzimidazol-2-amine derivatives.
• In vitro anti-proliferative assays using the A549 cell line.

Main Results:

• Docking analysis confirmed conserved interactions of selected compounds with ROS-1 active site residues.
• Molecular dynamics simulations indicated stable complex formation.
• Compounds 3a and 3b exhibited significant anti-proliferative activity with GI50 values of 23.0 and 25.4 μM, respectively.
• Identification of promising lead compounds for further NSCLC drug development.

Conclusions:

• The synthesized benzimidazol-2-amine derivatives show potent anti-proliferative effects against NSCLC cells.
• Compounds 3a and 3b are identified as potential candidates for further investigation as ROS-1 inhibitors.
• This study highlights the utility of structure-based drug design in developing novel anti-cancer agents.